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HCMV pUS28 initiates pro-migratory signaling
via activation of Pyk2 kinase
Jennifer Vomaske1, Susan Varnum2, Ryan Melnychuk1, Patricia Smith1, Ljiljana Pasa-Tolic2,
Janani I Shutthanandan2, Daniel N Streblow1*

Abstract
Background: Human Cytomegalovirus (HCMV) has been implicated in the acceleration of vascular disease and
chronic allograft rejection. Recently, the virus has been associated with glioblastoma and other tumors. We have
previously shown that the HCMV-encoded chemokine receptor pUS28 mediates smooth muscle cell (SMC) and
macrophage motility and this activity has been implicated in the acceleration of vascular disease. pUS28 induced
SMC migration involves the activation of the protein tyrosine kinases (PTKs) Src and Focal adhesion kinase as well
as the small GTPase RhoA. The PTK Pyk2 has been shown to play a role in cellular migration and formation of
cancer, especially glioblastoma. The role of Pyk2 in pUS28 signaling and migration are unknown.
Methods: In the current study, we examined the involvement of the PTK Pyk2 in pUS28-induced cellular motility.
We utilized in vitro migration of SMC to determine the requirements for Pyk2 in pUS28 pro-migratory signaling.
We performed biochemical analysis of Pyk2 signaling in response to pUS28 activation to determine the
mechanisms involved in pUS28 migration. We performed mass spectrometric analysis of Pyk2 complexes to identify
novel Pyk2 binding partners.
Results: Expression of a mutant form of Pyk2 lacking the autophosphorylation site (Tyr-402) blocks pUS28mediated SMC migration in response to CCL5, while the kinase-inactive Pyk2 mutant failed to elicit the same
negative effect on migration. pUS28 stimulation with CCL5 results in ligand-dependent and calcium-dependent
phosphorylation of Pyk2 Tyr-402 and induced the formation of an active Pyk2 kinase complex containing several
novel Pyk2 binding proteins. Expression of the autophosphorylation null mutant Pyk2 F402Y did not abrogate the
formation of an active Pyk2 kinase complex, but instead prevented pUS28-mediated activation of RhoA.
Additionally, pUS28 activated RhoA via Pyk2 in the U373 glioblastoma cells. Interestingly, the Pyk2 kinase complex
in U373 contained several proteins known to participate in glioma tumorigenesis.
Conclusions: These findings represent the first demonstration that pUS28 signals through Pyk2 and that this PTK
participates in pUS28-mediated cellular motility via activation of RhoA. Furthermore, these results provide a
potential mechanistic link between HCMV-pUS28 and glioblastoma cell activation.

Background
Human cytomegalovirus (HCMV) is a beta-herpesvirus
able to establish a life-long persistent infection after primary infection has been cleared. Although infection is
ubiquitous in the human population, persistent HCMV
infection is commonly asymptomatic in healthy, immunocompetent individuals. However, HCMV causes significant disease in immunosuppressed patients and,
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despite effective antiviral therapies, HCMV infection is
still a significant problem in congenital disease and in
bone marrow transplant recipients. Additionally, HCMV
has been associated with long-term diseases including
the vascular diseases atherosclerosis, restenosis following
angioplasty, and chronic allograft rejection following
solid organ transplantation [1-4]. Recently, HCMV has
been detected in human glioblastomas, and it has been
suggested that HCMV exacterbates the progression of
this disease [5]. Chemokines and their receptors have
been identified as key mediators in chronic inflammatory processes that attend the development of vascular
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diseases and play a role in tumor development. Herpesviruses manipulate the host chemokine system by regulating the expression of host chemokines and
chemokine receptors as well as by encoding chemokine
and chemokine receptor homologues. Indeed, HCMV
encodes a CXC chemokine (UL146), a putative CC chemokine (UL128), and four potential chemokine receptors (US27, US28, UL33 and UL78). pUS28 is one of the
best characterized chemokine receptors and has been
implicated in the development of long-term pathologies
associated with HCMV infection, including vascular disease and malignancies [6-10].
pUS28 contains homology to the CC-chemokine
receptors [11] and binds to a broad spectrum of CCchemokine ligands, including RANTES/CCL5, MCP-1/
CCL2, MCP-3/CCL7, and MIP-1b/CCL4. pUS28 is unusual in that it is able to bind the CX3C-chemokine Fractalkine/CX3CL1 with high affinity in addition to binding
a variety of CC-chemokines [12,13]. Although the
N-terminal 22 amino acids of pUS28 have been shown
to be essential for binding of both chemokine classes,
CC-chemokines fail to compete with CX3CL1 for receptor occupation. Mutagenesis studies of pUS28 indicate
that different N-terminal residues are critical for binding
to each chemokine class [12,14]. Chemokine binding to
pUS28 initiates a variety of cellular signaling pathways
[15-18]. Additionally, pUS28 has been shown to signal
constitutively in the absence of ligand binding in several
transformed cell lines [19]. pUS28 mediated migration
of arterial SMC requires binding of the CC-chemokines
CCL5 or CCL2 [20], while CX3CL1 inhibits pUS28mediated SMC migration via the CC-chemokines [18].
However, CX3CL1 does actively promote the robust
migration of pUS28 expressing macrophages suggesting
that pUS28 has a dual function dependent upon the cell
type it is expressed in and the local chemokine environment of that cell [18]. The binding of each chemokine
ligand class (CC- vs. CX3C-) results in differential signaling at the level of G-protein coupling to pUS28 [18].
In fact, pUS28 binding to the CC-chemokines promotes
SMC migration through the activation of Ga12/13 and
the small G-protein RhoA. pUS28-mediated SMC
migration can be blocked by expression of a dominant
negative RhoA or RhoA effector associated kinase-1
(ROCK-1) [16].
pUS28 signals through the non-receptor tyrosine kinases
focal adhesion kinase (FAK) and Src in a ligand-dependent
manner, and this activity is required for induction of
pUS28-mediated SMC migration. [17]. FAK is comprised
of a central kinase domain flanked on one side by an Nterminal FERM (erythrocyte band 4.1-ezrin-radixinmoesin) domain, which is involved in linking FAK to
integrins and growth factor receptors and provides regulation of the Tyr-397 autophosphorylation site [21,22].
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Additionally, the FERM domain regulates FAK kinase
activity via direct interaction with the kinase domain
thereby blocking the access of substrates to the catalytic
cleft [23]. The F.A.T. (focal adhesion targeting) domain is
located C-terminal of the central kinase domain and is
comprised of multiple protein-protein interaction motifs.
FAK tyrosine phosphorylation following cellular stimulation is enhanced by its association with Src-family PTKs at
Tyr-397. pUS28-mediated SMC migration is sensitive to
the Src inhibitor PP2 and mutation of the FAK autophosphorylation site at Tyr-397 blocks SMC migration in a
dominant-negative fashion. Conversely, a kinase-negative
FAK mutant (FAK R454K) had no effect on pUS28mediated SMC migration [17] suggesting that FAK acts as
a protein scaffold rather than an active kinase in the signaling cascade leading to SMC migration.
Proline-rich Tyrosine kinase 2 (Pyk2), also a nonreceptor tyrosine kinase, is highly related to FAK and
plays an important role in cell motility [24]. Recently,
Pyk2 has been shown to be involved in the CCR5mediated chemotaxis of dendritic cells via binding of
HIV-1 gp120 [25]. In addition, Pyk2 is critical for
Angiotensin II (AngII)-mediated migration of vascular
SMC (VSMC), in which Pyk2 mediates activation of
RhoA and its effector kinase ROCK via phosphorylation
of PDZ-Rho-GEF [26,27].
FAK and Pyk2 share an overall 45% sequence homology with 60% identity within the catalytic domain and
also have analogous sites for tyrosine phosphorylation
and Src binding [28]. Despite their striking sequence
similarity, it is becoming increasingly clear that these
molecules play very different roles in signaling cascades
leading to cellular migration. Pyk2 is expressed in cells
of the brain, hematopoetic cells, osteoblasts, some types
of epithelium, SMC and fibroblasts [24]. Unlike FAK,
Pyk2 activation has a significant dependence on intracellular calcium levels [28,29]. Calcium-mediated regulation of Pyk2 activity proceeds via binding of Ca2
+/calmodulin to the Pyk2 FERM domain, allowing
homodimerization and autophosphorylation at Tyr-402
[30]. Autophosphorylation of Pyk2 is believed to be a
critical initial step in the activation of Pyk2 via the
recruitment of Src to the phosphorylated Tyr-402 site,
resulting in further tyrosine phosphorylation of Pyk2
[31,32]. However, Pyk2 activation can proceed by both
Src-dependent [31,33-35] and Src-independent [36,37]
mechanisms. Additionally, Pyk2-mediated phosphorylation of paxillin has been demonstrated to be independent of Tyr-402 autophosphorylation in SYF cells [32].
Collectively these data demonstrate that Tyr-402 autophosphorylation is not absolutely required for Pyk2 activity. While Pyk2 can partially compensate for the lack of
FAK in fibroblasts derived from FAK-/- mouse embryos,
Pyk2 alone is not sufficient to reconstitute a migratory
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phenotype in these cells [34]. Pyk2 and FAK interact in
signaling events leading to cellular migration [38-41],
but the relationship between these two proteins remains
poorly defined and appears to be highly signal and cell
context-specific Additionally, phosphorylation kinetics
differ between the two proteins [37].
Here, we examined the involvement of Pyk2 in
pUS28-induced signaling and SMC migration. Pyk2 is
activated in SMC expressing pUS28 following the addition of ligand in a calcium-dependent manner. Expression of the autophosphorylation site mutant of Pyk2
(F402Y) blocks SMC migration in a dominant-negative
fashion by preventing RhoA activation, while the kinaseinactive mutant has no effect on migration. Pyk2 forms
an active kinase complex containing several novel Pyk2
binding proteins in CCL5 stimulated SMC expressing
pUS28. Suprisingly, the autophosphorylation null
mutant Pyk2 F402Y did not abrogate the formation of
an active Pyk2 kinase complex but did prevent the
pUS28-mediated activation of RhoA. Lastly, we demonstrate the pUS28-mediated activation of RhoA via Pyk2
also occurs in U373 glioblastoma cells. The Pyk2 kinase
complex in U373 is distinct from the complex observed
in RSMC and contains a number of proteins known to
participate in glioma tumorigenesis. These results provide a potential mechanistic link between pUS28 signaling and glioma pathogenesis.

Methods
Cell Lines

The life-extended telomerized pulmonary artery SMC
line, PAT1 [16] were maintained in Medium 199 supplemented with 20% fetal calf serum (FCS) and penicillinstreptomycin-L-glutamine (PSG; Gibco). For migration
experiments described below, PAT1 cells were utilized
between passage 5 and 30 post-telomerization. Mouse
FAK-/- fibroblasts were maintained on gelatin coated
culture dishes in Dulbecco’s modified Eagle’s Medium
(DMEM) supplemented with 10% FCS, PSG, non-essential amino acids (Cellgro), and G418 (Sigma; 500 μg/ml)
as previously described [34,42]. FAK-/- cells used in
experiments were between passage 5 and 15. Primary
F344 rat SMC (RSMC) were maintained in Dulbecco’s
modified Eagle’s Medium (DMEM) with 10% FCS and
PSG. RSMC were used between passage 5 and 20. U373
glioblastoma cells were maintained in DMEM supplemented with 10% FCS and PSG. U373 were used
between passage 5 and 20.
Reagents

Recombinant human CCL5 was purchased from R&D
Systems and BAPTA-AM was from Sigma-Aldrich
(A1076). Anti-Pyk2 (N-19), anti-phospho-402-Pyk2,
anti-myc (9E10), anti-RhoA and anti-HA (F-7)
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antibodies were purchased from Santa Cruz Biotechnology. Secondary anti-mouse, anti-goat and anti-rabbit
horseradish peroxidase (HRP)-conjugated antibodies
were purchased from Amersham. Goat anti-mouse
Alexa Fluor-488 was purchased from Molecular Probes
(A11017).
Adenovirus Construction

The adenovirus expressing pUS28-HA was previously
described [20,43,44]. Myc-tagged Pyk2 WT, Pyk2
A457K (kinase inactive mutant) or Pyk2 F402Y (autophosphorylation mutant) [34] were constructed by cloning of the cDNA into pAdTet7, which contains the
tet-responsive enhancer within a minimal CMV promoter followed by the SV40 late poly(A) cassette.
Recombinant adenoviruses were produced by co-transfection of 293 cells expressing the Cre-recombinase
with pAdTet7 constructs and adenovirus DNA (Ad5Ψ5, an E1A/E3-deleted adenovirus genome) [45].
Recombinant adenoviruses were expanded on 293-Cre
cells and the bulk stocks were titered on 293 cells by
limiting dilution. Gene expression was driven by coinfection with an adenovirus expressing the Tet-off
transactivator (Ad-Trans) [20].
SMC migration assay

Cell migration assays were performed as previously
described [20]. PAT1 cells were infected with HCMV
(MOI 10) for 2 hrs followed by co-infection with AdTrans and Ad-Pyk2 (WT, A457, F402Y) at MOI of 50
for an additional 2 hrs. Subsequently, the transwells
were transferred to new 12-well plates containing fresh
medium with CCL5 (50 ng/ml) added to the lower
chamber. Cells migrating into the lower chamber were
counted at 48-72 hours post-infection (hpi) using a
Nikon TE300 microscope at magnification 10×. Experiments were performed in at least triplicate wells and ten
random fields were read in each well. The average number of cells per well was determined by multiplying the
average number of cells per 10× field by the number of
fields per well. Mean and standard deviation were calculated. Pyk2 recombinant protein levels were monitored
by western blotting and equalized by adjusting the adenoviral vector MOI accordingly.
Immunofluorescence

Subcellular localization of adenovirus-expressed proteins
was visualized by fixing adenovirus-infected SMC in
4-well chamber slides (Nunc Lab-Tek) at 24 hpi in 2%
paraformaldehyde for 15 min. Cells were then permeablized with PBS containing 0.2% Saponin and 0.02%
BSA (sapPBS) for 15 min. Anti-myc primary antibody
was diluted 1:500 in sapPBS and cells were incubated
for 1 hr at room temperature (r.t.), washed twice with
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sapPBS, and incubated with goat anti-mouse Alexa
Fluor-488 diluted 1:1000 in sapPBS for 30 min at r.t.
After two more washes in sapPBS cells were visualized
on a Deltavision deconvolution fluorescence microscope
(Applied Precision).
Pyk2 Y402 Phosphorylation Assay

FAK-/- or U373 cells plated onto 6-well culture dishes at
50% confluence were serum-starved for 6 hrs. The cells
were infected with Ad-Trans and Ad-pUS28 at MOI 150
with Ad-Pyk2 or Ad-Pyk2 F402Y at MOI 50 and placed
in serum free medium. For calcium chelation assays, cells
were pre-treated with 50 μM BAPTA-AM for 30 min
prior to stimulation. At 16 hpi, the cells were stimulated
with CCL5 (40 ng/ml) and then scraped in 2× Laemmeli’s
Sample Buffer. Unboiled samples were loaded on 10%
SDS-PAGE. The gels were transferred to Immobilon-P
membranes then blocked in PBS containing 3% milk +
0.1% Tween 20 for 15 min at r.t. The primary anti-Phospho-Y402 Pyk2 rabbit polyclonal antibody was added at
1:1000 dilution in blocking buffer for 1 hr at r.t. The
blots were washed with TBS-Tween buffer (10 mM Tris
pH 7.2, 100 mM NaCl, 0.2% Tween-20). The secondary
antibody (goat anti-rabbit conjugated to HRP) was added
at 1:20,000 dilution in blocking buffer for 30 min at r.t.
After washing 3 times with TBS-Tween buffer and incubation with ECL reagents, the blots were visualized by
autoradiography. Blots were dried to inactivate the HRP
secondary reagent and then reprobed as above with antiPyk2 goat polyclonal antibody at 1:1000 dilution in
blocking buffer followed by secondary donkey anti-goat
conjugated to HRP at 1:100,000 dilution.
RhoA Activation Assay

FAK-/- or U373 cells plated onto 6-well culture dishes
at 50% confluence were serum-starved for 6 hrs. The
cells were infected with Ad-Trans only or co-infected
with Ad-Trans and Ad-pUS28 at MOI 150 with or without Ad-Pyk2 or Ad-Pyk2 F402Y at MOI 50 and placed
in serum free medium. After 16 hrs, the cells were stimulated with CCL5 (40 ng/ml) and then scraped in
equal volumes modified RIPA buffer (10 mM Tris
pH7.4, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100,
1% Sodium Deoxycholate, 0.1% SDS) containing protease inhibitor cocktail (100 mM AEBSF, 80 μM aprotinin, 1.5 mM E-64, 2 mM leupeptin hemisulfate, and
1 mM pepstatin A) at 0 (unstimulated), 2.5, 5, or 10
minutes post-stimulation. Cell lysates were homogenized
via sonication, then incubated with 20 μl Rho Assay
Reagent (Rhotekin-RBD-GST Agarose; Upstate) for 1 hr
at 4°C, then washed 3 times with 1 ml of RIPA. The
final bead pellet was resuspended in 40 μl of 2×
Laemmli’s sample buffer, boiled and then run on 10%
SDS-PAGE. The gels were transferred to Immobilon-P
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membranes then blocked in blocking buffer (PBS containing 3% Milk + 0.1% Tween 20) for 15 min at r.t.
The primary anti-RhoA mouse monoclonal antibody
was added at 1:1000 dilution in blocking buffer for 1 hr
at r.t. The blots were washed with TBS-Tween buffer.
The secondary antibody (goat anti-mouse conjugated to
HRP) was added at 1:40,000 dilution in blocking buffer
for 30 min at r.t. After washing 3 times with TBSTween buffer and incubation with ECL reagents, the
blots were visualized by autoradiography.
Pyk2

In Vitro Kinase Assays. In vitro kinase assays were performed on on immunoprecipitated Pyk2 from F344 aortic
RSMC. Cells were plated in 10 cm culture dishes and
serum starved for 24 hrs. The RSMC were co-infected
with Ad-Trans and Ad-Pyk2 or Ad-Pyk2 F402Y at an
MOI of 50 with or without Ad-pUS28 at an MOI of 150.
After 16 hrs, the cells were stimulated with recombinant
human CCL5 (40 ng/ml) and then harvested at times 0
(unstimulated), 2.5, 5, 10, and 15 minutes post ligand addition. Cells were rinsed in PBS and lysed in modified RIPA
containing protease inhibitor cocktail and 200 μM sodium
orthovanadate. Total Pyk2 was immunoprecipitated using
mouse anti-myc tag monoclonal antibody and Protein-A/
G conjugated agarose beads (Santa Cruz Biotechnology).
Precipitation reactions were washed one time in Tritononly lysis buffer (modified RIPA without sodium deoxycholate and SDS), two times in HNTG buffer (50 mM
HEPES, 150 mM NaCl, 1% Triton, 10% Glycerol, pH 7.4),
and two times in kinase buffer (20 mM HEPES, 10 mM
MgCl2, 10 mM MnCl2, 150 mM NaCl, 10% Glycerol pH
7.4) and then resuspended in 50 μl kinase buffer plus 10
μCi 32P-g-ATP (Perkin-Elmer). The kinase reaction was
allowed to proceed for 30 minutes at r.t. then stopped by
the addition of 2× Laemmeli’s sample buffer. After boiling
for 5 minutes, the reactions were run on 10% SDS-PAGE
and transferred to Immobilon-P membranes. The incorporation of 32P-g-ATP was visualized via autoradiography.
After allowing radioactivity to decay, the membranes were
further analyzed via western blot as above for the presence
of Pyk2-myc and pUS28-HA.
Preparation of Pyk2 Complexes for Proteomics Analysis

Proteomics analysis was performed on immunoprecipitated Pyk2 from F344 aortic RSMC or U373 glioblastoma cells. Cells were plated in 15 cm culture dishes.
The RSMC were serum starved for 24 hrs prior to coinfection with Ad-Trans and Ad-Pyk2 at an MOI of 50
with or without Ad-pUS28 at an MOI of 150. After
16 hrs, the cells were stimulated with recombinant
human CCL5 (40 ng/ml) and then triplicate dishes were
harvested at times 0 (unstimulated), 5, 10, 15, 30 and
60 minutes post ligand addition. Cells were rinsed in
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PBS and lysed in modified RIPA containing protease
inhibitor cocktail and 200 μM sodium orthovanadate.
Total Pyk2 was immunoprecipitated using mouse antimyc tag monoclonal antibody and Protein-A/G conjugated agarose beads (Santa Cruz Biotechnology). Precipitation reactions were washed twice with RIPA. Pyk2 and
associated proteins were eluted with 200 μl of Pierce
Gentle Ag/Ab Elution buffer. Triplicate eluates were
combined and the samples were sequenced by tandem
mass spectrometry analysis at the EMSL user facility at
Pacific Northwest National Laboratories.
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released January 2009). MS/MS peaks were generated by
“extract_msn.exe,” part of the SEQUEST software package. A peptide was considered to be a match by using a
conservative criteria set developed previously by Yates
and coworkers [45]. Briefly, peptides were retained if
they met the following criteria: 1). SEQUEST DelCN
value of ≥0.1 and 2). SEQUEST correlation score
(Xcorr) > 1.9 for charge state 1+ and fully tryptic; Xcorr
> 2.2 for charge state 2+ and fully or partially tryptic;
Xcorr > 3 for charge state 2+ regardless of tryptic state;
Xcorr > 3.75 for charge state 3+ for fully or partially
tryptic.

Tryptic digestion of Pyk2 Complexes

Proteins from the Pyk2 complexes were desalted and concentrated with Amicon ultra filtration units (Millipore,
Billerica, MA). Protein concentration was determined
using BCA protein assay (Thermo Scientific) and the concentrated protein was denatured by the addition of trifluoroethanol (TFE) to a final concentration of 50% and
heating to 37°C for 60 min. Denatured proteins were
reduced with DTT (2 mM final concentration) and diluted
fivefold with 50 mM NH4HCO3. Methylated, sequencinggrade porcine trypsin (Promega, Madison, WI) was added
at a substrate-to-enzyme ratio of 50:1 (mass to mass) and
incubated at 37°C for 3 hrs. The peptides were concentrated with a speed vac and stored at 80°C until analysis.
Tandem mass spectrometric analysis of peptides

Peptide samples were analyzed using an automated custom built capillary LC system containing a four capillary
column system (Livesay et al, Anal Chem 2008, vol 80,
page 294). Eluate from the LC was coupled directly to a
hybrid linear ion-trap-orbitrap (LTQ_Orbitrap, Thermo
Electron Corp.). The reverse-phase capillary column was
prepared by slurry-packing 3-micron Jupiter C18
bonded particles (Phenomenex, Torrence, CA) into a 65
cm long, 75-micron-inner diameter fused silica capillary
(Polymicro Technologies, Phoenix, AZ). After peptide
loading onto the column, the mobile phase was held at
100% A (0.05% trifluoroacetic acid (TFA) and 0.2%
acetic acid in water) for 20 min, followed by a linear
gradient from 0 to 70% buffer B (0.1% TFA in 90% acetonitrile, 10% water) over 80 min with a flow rate of
~500 nL/min. Orbitrap spectra (AGC 1 × 106) were collected from 400-2000 m/z at a resolution of 100 k followed by data-dependent ion trap tandem mass spectra
(AGC 1 × 104 ) of the six most abundant ions using a
collision energy of 35%. The heated capillary was maintained at 200°C, and the ESI voltage was held at 2.2 kV.

Results
Pyk2 Autophosphorylation is Required for pUS28mediated SMC Migration

In order to establish the involvement of Pyk2 in
pUS28-mediated SMC migration, we constructed a
panel of adenovirus vector expressing myc-tagged versions of wild-type Pyk2 (Pyk2-WT), an autophosphorylation null mutant (Pyk2-F402), and a kinase-inactive
mutant (Pyk2-A457) (Figure 1A) [34]. These Pyk2
mutant adenoviruses were expressed in human pulmonary artery smooth muscle (SMC) cells. Gene
expression was driven by co-infection with the Tet-off
transactivator adenovirus (Ad-Trans) and Ad-Trans
infection alone is used to control for any non-specific
effects of adenovirus infection. All Pyk2 constructs
displayed similar cellular distribution patterns in the
cytoplasm and at lamellipodia of growing cells (Figure
1B). As previously described, human SMC cells
infected with HCMV migrated in response to CCL5
[20,46] (Figure 1C). Expression of Pyk2-WT produced
similar levels of migration compared to Ad-Trans
only controls. Surprisingly, co-infection with adenovirus producing kinase-inactive Pyk2 (Pyk2-A457) did
not abrogate HCMV-mediated SMC. In contrast,
expression of a mutant Pyk2 that lacks the Tyr-402
autophosphorylation site (Pyk2-F402) acted as a
dominant negative inhibitor of HCMV-mediated SMC
migration, causing a 60% reduction in SMC migration
compared to HCMV-infected SMC expressing Pyk2WT (Figure 1C). These results demonstrate that Pyk2
kinase activity is dispensable for pUS28-mediated
SMC migration and suggest that the primary role of
Pyk2 in the pro-migratory signaling cascade in these
cells is to act as a signaling scaffold for the activation
of Src kinase [31].

SEQUEST analysis

pUS28 Signaling leads to Phosphorylation of Pyk2 at
Y402

The SEQUEST algorithm was run on each of the datasets against the human.fasta from the International Protein Index database (version 3.54, 75,419 entries,

In order to further characterize the role of Pyk2 in
pUS28-mediated cellular migration, we examined phosphorylation of Pyk2 at Y402 in Ad-pUS28 infected
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cells similarly stimulated. CCL5 stimulation had a small
but quantifiable effect on Pyk2 phosphorylation in
FAK-/- cells infected with Trans only, we believe this
activation is attributable to the effects of calcium gradients produced by the addition of media upon stimulation (Figure 2A). Pyk2 kinase activity has been shown to
be dependent on intracellular calcium levels [28-30].
Therefore, we treated pUS28-expressing FAK-/- with
BAPTA-AM to chelate intracellular calcium prior to
performing signaling assays. The cells were then stimulated with CCL5 and examined for Pyk2 Y402 phosphorylation via western blot. As expected, chelation of
intracellular calcium abrogated phosphorylation of Pyk2
in response to pUS28 signaling (Figure 2B) and prevented Pyk2 activation in Ad-Trans controls (data not
shown). We observed a low, but measurable, effect of
US28 expression on Pyk2 activity in the absence of
ligand (Figure 2A and 2B), which could be attributed to
either low-level constitutive signaling or minor effects of
endogenously expressed ligands.
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Figure 1 Pyk2 Autophosphorylation Mutant Inhibits HCMVmediated SMC. (A) Schematic of Pyk2 domain structure with
A457K and F402Y mutations annotated. (B) Sub-cellular localization
of myc-tagged adenovirus constructs was determined via indirect
immunofluorescence staining for the myc epitope. From left AdPyk2 WT, Ad-Pyk2-F402Y and Ad-Pyk2-A457K in lamellipodia of
adenovirus-infected PAT1 SMC. Gene expression was driven my coinfection with an adenovirus expressing the Tet-off transactivator
(Ad-Trans) (C) SMC migration assays were performed on PAT1 SMC
co-infected with HCMV at MOI 10 and adenoviruses expressing
control Ad-Trans only or Ad-Trans+Pyk2-WT, Pyk2-A457K, or Pyk2F402Y at MOI 50 in transwell chambers. At 2 hrs post-infection fresh
medium containing 50 ng/ml CCL5 was added to the bottom
chamber and cells were allowed to migrate for 48 hrs. Migrated
cells in the lower chamber were counted via light microscopy. For
each condition, n = 6 from two independent experiments.
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mouse fibroblasts lacking FAK (FAK-/-). FAK-/- cells are
known to have elevated levels of endogenous Pyk2, partially compensating for the lack of FAK [34,47]. We have
utilized FAK-/- for pUS28 signaling assays in previous
studies [17,18]. FAK-/- exhibit low baseline activation of
pro-migratory signaling molecules and are therefore a
highly inducible system in which to study these signaling
events. Furthermore, using this system we can study
pUS28 signaling to Pyk2 independent of FAK.
pUS28-expressing FAK-/- stimulated with CCL5
showed sustained phosphorylation of Pyk2 at Y402.
Levels of Pyk2 phosphorlyation were ~2-fold higher in
the presence of pUS28 than control Ad-Trans infected
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Figure 2 pUS28 Signaling Causes Calcium-Dependent
Phosphorylation of Pyk2 at Y402. (A) FAK-/- fibroblasts were
infected with Ad-Trans only or Ad-Trans+Ad-pUS28 for 18 hrs. Cells
were stimulated with 40 ng/ml CCL5 for the indicated times and
analyzed via western blot with a phospho-specific Pyk2-Y402
antibody or total Pyk2 antibody. (B) Adenovirus-infected FAK-/- were
pre-treated for 30 min with BAPTA-AM to chelate intracellular
calcium and then stimulated with 40 ng/ml CCL5 for 5 min. Total
cell lysates were analyzed via western blot for phospho-Y402 Pyk2
and total Pyk2. For both experiments, blots were stripped and
reprobed to verify pUS28-HA expression. Phospho-specific blots
were quantified via densitometry using ImageJ software and are
expressed as fold change compared to unstimulated, Ad-Trans
infected control.
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Identification of Pyk2 Binding Partners

We performed proteomics analysis on Pyk2 kinase complexes in order to determine whether pUS28 signaling
promotes the association of Pyk2 with novel binding partners. We isolated Pyk2 complexes via immunoprecipitation as described above from RSMC expressing pUS28HA and Pyk2 at 0, 5, 10, 15, 30 or 60 min post-addition of
CCL5. As a control for the pUS28-specificity of Pyk2
interactions, we performed identical immunoprecipitation
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We have shown that phosphorylation of Pyk2 at Y402 is
required for SMC migration (Figure 1C) and that pUS28
signaling causes phosphorylation at this critical site
independent of any pUS28 activation of FAK (Figure
2A). Although activation at the autophosphorylation site
is important for Pyk2 function [32], we wanted to
further characterize the effect of pUS28 signaling on the
activation and function of Pyk2. To accomplish this, we
performed in vitro kinase assays on Pyk2 immunoprecipitation reactions. For these experiments we returned to
examining Pyk2 signaling in the context of SMC. However, in human SMC endogenous production of pUS28
ligands obscures signaling activation [48]. Therefore, as
in previous studies [18], we chose to perform these
experiments in primary rat SMC (RSMC) to eliminate
this background signaling. Cells were serum starved and
co-infected with adenovirus vectors expressing Pyk2WT with or without pUS28-HA. The cells were then
stimulated with either 20% serum, as a positive control
for Pyk2 activation, or 40 ng/ml CCL5 and harvested at
0, 2.5, 5, 10 or 15 min post-stimulation. Pyk2 was then
immunoprecipitated from total cell lysates using a
monoclonal antibody directed against the myc tag and
immunoprecipitated proteins were subjected to in vitro
kinase assay. The Pyk2 kinase activity was analyzed via
SDS-PAGE and autoradiography. pUS28 signaling promoted the formation of a large kinase complex involving
Pyk2 and a number of other interacting phosphoproteins. This protein complex begins to form by 2.5 min
after the addition of CCL5 peaking at 10 min post
ligand treatment (Figure 3A and 3C). Plotting the optical density of unstimulated versus 5 min stimulated
timepoints using ImageJ software revealed several
pUS28-specific proteins associated with Pyk2 (Figure
3B). When a parallel experiment was performed in the
presence of Pyk2-F402Y, a similar kinase complex was
observed (data not shown), indicating that Tyr-402 is
not critical for formation or maintenance of Pyk2 in an
active kinase complex but rather mediates the binding
of critical signaling elements necessary for the Pyk2
scaffold to participate in pro-migratory signaling.
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pUS28 Signaling Causes formation of a Pyk2-Associated
Active Kinase Complex
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Figure 3 pUS28 Signaling Causes Formation of an Active
Kinase Complex Involving Pyk2. SMC were infected with Ad-Trans
and Ad-Pyk2 +/- Ad-pUS28 and stimulated with 20% serum or 40
ng/ml CCL5 for indicated times. Pyk2 was immunoprecipitated
using myc antibodies. In vitro kinase reactions were performed on
immunoprecipitated material and reactions were loaded on SDSPAGE, transferred to immobilon-P membranes and visualized via
autoradiography. (A) Autoradiogram of in vitro kinase reactions.
Total Pyk2 and pUS28 expression was determined by western blot
for myc and HA tags, respectively. (B) Densitometric lane plots of
results shown in panel A, generated using ImageJ software. The
darker curve (overlay) is unstimulated and the lighter curve
(background) is 5 min post-stimulation for Pyk2 only stimulated
with serum (top) or Pyk2+pUS28 stimulated with CCL5 (bottom).
Black arrows indicate bands present only in stimulated samples.
Molecular weight markers are shown on the density plot to
facilitate comparison to the autoradiogram in panel A. (C) Overall
optical density quantification of each lane in Pyk2 in vitro kinase
reactions shown in panel A. Values are displayed as percentages
compared to unstimulated samples infected with Ad-Trans+Ad-Pyk2.

reactions in RSMC expressing Pyk2 only stimulated with
20% serum. Bound proteins were analyzed via tandem
mass spectrometry. We identified a total of 50 Pyk2 binding partners in RSMC and 24 of these associated with
Pyk2 specifically in response to pUS28 expression. Only 6
proteins were specific for Pyk2 in the absence of pUS28
(Figure 4A Table 1 Additional File 1). When we examined
the proteins whose Pyk2 association was specifically
induced over the signaling timecourse, we determined that
34 proteins associated with Pyk2 in response to pUS28 stimulation by CCL5. In contrast, only 4 proteins were specifically activated by serum stimulation of RMSC expressing
Pyk2 only (Figure 4B). As expected, we identified a number of cytoskeleton structural proteins in our proteomics
screen confirming that Pyk2 is directly associated with the
cytoskeleton when activated [49] (Table 1 and Additional
File 1). We identified several proteins known to interact
with Pyk2 in other systems including calmodulin [50] and
gelsolin [51]. In support of our hypothesis that Pyk2 serves
as a scaffold for pUS28 signaling in RSMC, we found
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Pyk2 F402Y is Defective in RhoA Activation
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Figure 4 Pyk2-Associated Proteins are Cell-Type and SignalSpecific. SMC or U373 were infected with Ad-Trans and Ad-Pyk2
+/- Ad-pUS28 and stimulated with 20% serum or 40 ng/ml CCL5 for
0, 5, 10, 15, 30 or 60 min. Pyk2 was immunoprecipitated using myc
antibodies. Pyk2 complexes were analyzed via tandem mass
spectrometry. Results shown are proteins identified with >3 spectral
hits for all peptides. (A) Total hits for Pyk2-associated proteins in
RSMC and U373. (B) Proteins for which Pyk2-association was
induced over the timecourse of stimulation in RSMC and U373. For
data analysis, a protein was considered induced if the average
spectral hits for all peptides for timepoints 5, 10, 15, 30 and 60 min
was greater than twice the spectral hits for all peptides in
unstimulated cells.

several signaling intermediates associating with Pyk2 over
the timecourse. These included a RhoGEF (Trio) known
to link G-protein signaling to RhoA activation [52], a regulator of MAPK signaling (KSR-2) [53] as well as a regulator of the SHP-1 tyrosine phosphatase (TFG) [54].
Interestingly, we observed a pUS28 inducible association
of Pyk2 with the NFB precursor p105. Although Pyk2
signaling has been implicated in NFkB activation [55,56],
we believe that our data showing NFB p105 present in
an activated Pyk2 complex is novel in the literature. This
interaction may provide a secondary, ligand-dependent
mechanism for pUS28-mediated activation of NFB.

We have previously demonstrated that activation of RhoA
is necessary for pUS28-mediated SMC migration [16].
Therefore, we hypothesized that the dominant negative
effect of the Pyk2 F402Y mutant is due to a defect in
RhoA activation. To test this hypothesis, we performed a
RhoA activation assay in cells expressing pUS28 that were
stimulated with CCL5. For these experiments, RhotekinRhoA Binding Domain (RBD) conjugated beads were used
to specifically pull-down active RhoA from FAK-/- cells
expressing Trans only, or Trans + pUS28 with or without
Pyk2-WT or Pyk2-F402Y. Percent of RhoA activated was
calculated by comparing immunoprecipitated RhoA with
total RhoA in the same sample. As expected, within 5 min,
CCL5 stimulation of pUS28-expressing FAK-/- results in
activation of 68% of total RhoA compared to a maximum
of 27% activation in control Trans infected cells treated
with CCL5 (Figure 5). Overexpression of Pyk2-WT markedly raised baseline activation of RhoA in pUS28 expressing cells and resulted in the activation of 100% of RhoA
at 2.5 min post addition of CCL5. The phenomenon of
increased baseline activation of Pyk2 and downstream
effectors in the context of overexpression has been
observed by others, and appears to be due to the Ca 2
+
-mediated regulation of Pyk2 activity [30]. Conversely,
overexpression of Pyk2-F402Y abrogated pUS28-mediated
activation of RhoA, resulting in a maximum of 10% activation over the timecourse of stimulation (Figure 5). We
observed some cellular toxicity in samples overexpressing
Pyk2 F402Y which resulted in slightly lower total RhoA
levels in these samples, but as each sample was internally
controlled we believe this has no effect on the data as
shown. These results demonstrate that activation of Pyk2
at Y402 is necessary for Pyk2-mediated signaling to RhoA
and subsequent signaling leading to SMC migration.
pUS28 Activates Pyk2 in Glioblastoma Cells

Having established a functional link between pUS28,
Pyk2 and migration in SMC, we hypothesized that
pUS28 mediates pro-migratory signaling to Pyk2 in
other CMV-susceptible cell types. Although HCMV

Table 1 Pyk2 binding partners in pUS28-expressing RSMC
CATEGORY
Cytoskeleton Structure and
Dynamics
Signal Transduction
Inflammation and Immunity
Cellular Proliferation

PROTEIN(S) IDENTIFIED
b-actin, a1-actin, F-actin capping proteins-a1, -a2*, and -b, Gelsolin [51,72,88,89], Myosin-9, -10, -11, Myosin light
chain-6, Tropomodulin-3 [72], Tropomyosin-a1, a3, a4 -b [72,90,91], Tubulin-b-2C, Vimentin [92]
Calmodulin [30,50], G-protein subunit b5 [93], KSR-2* [53,94], Rhophilin-2* [95], Trio* [52,96], TFG [54]
Immunoglobulin lambda light chain [97], NFB p105
AF-17 [98], RTEL-1* [99]

Boldface font indicates proteins identified as Pyk2-associated in multiple cell types.
* indicates proteins identified with low abundance (< 3 spectral hits on a single peptide).
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Figure 5 Pyk2-F402Y Blocks pUS28 Signaling to RhoA. FAK-/fibroblasts were infected with Ad-Trans and Ad-pUS28 +/- Pyk2-WT
or -F402Y for 18 hrs. Cells were stimulated with 40 ng/ml CCL5 for
the indicated times. Lysates were immunoprecipitated with
Rhotekin-RBD-GST Agarose and analyzed by western blot for RhoA.
Input lysates were analyzed for total RhoA and to confirm
adenovirus infection efficiency. The percent active RhoA was
quantified via ImageJ densitometry of both IP and total lysate
western blots.

infection has been associated with poor clinical outcome
in glioblastoma multiforme (GBM) patients, a clear
mechanistic link between HCMV and GBM tumorigenesis has not been established [5,46,57]. However, many
studies have associated aberrant activation of Pyk2 with
increased invasiveness in GBM [41,58-60]. To test
whether pUS28 can signal to Pyk2 in a glioma model,
we examined phosphorylation of Pyk2 at the Y402 site
in pUS28 adenovirus infected U373. Interestingly, we
observed pUS28-specific phosphorylation of Pyk2 in
U373 in response to both CCL5 and CX3CL1 stimulation (Figure 6A). Interestingly, Pyk2 phosphorylation in
response to CX3CL1 stimulation is biphasic, with two
separate peaks of phosphorlyation, the first at 2.5 and
second at 10 min post-ligand addition. This biphasic
pattern of phosphorylation at the Y402 site has been
observed in other systems [37].
We tested the participation of Pyk2 in the pUS28mediated activation of RhoA in this system. Similar to
results obtained in FAK-/- fibroblasts, pUS28-specific
activation of RhoA is readily observed in U373. pUS28expressing U373 showed 49% activation of RhoA at 5
min post addition of CCL5. Adenovirus expression of
WT Pyk2 resulted in similar activation of RhoA, but
altered the timing of RhoA activation such that the peak
of RhoA activation was seen at 2.5 min post addition of
CCL5. Overexpression of the Pyk2 F402Y mutant prevents pUS28-mediated activation of RhoA resulting in
less than 1% activation of RhoA throughout the timecourse of stimulation (Figure 6B).
In order to compare pUS28-mediated activation of
Pyk2 in U373 to that seen in RSMC, we performed proteomics analysis of Pyk2 complexes in U373 (Figure 4
Table 2 and Additional File 2). The conditions for this
experiment were the same as the previous experiment
in RSMC. Overall, Pyk2 seems to have a greater number
of binding partners in U373 underscoring the importance of Pyk2 in glioma cell biology. A total of 73
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Figure 6 pUS28 Activates Pyk2 and RhoA in U373
Glioblastoma Cells. (A) U373 cells were infected with Ad-Trans or
Ad-pUS28 for 18 hrs. Cells were stimulated with 40 ng/ml CCL5
(left) or 40 ng/ml CX3CL1 (right) for the indicated times and
analyzed via western blot with a phospho-specific Pyk2-Y402
antibody or total Pyk2 antibody. (B) U373 were infected with AdTrans, Ad-pUS28 or Ad-pUS28 + Pyk2 WT or F402Y for 18 hrs. Cells
were stimulated with 40 ng/ml CCL5 for the indicated times.
Lysates were immunoprecipitated with Rhotekin-RBD-GST Agarose
and analyzed by western blot for RhoA. Input lysates were analyzed
for total RhoA and to confirm adenovirus infection efficiency. The
percent active RhoA was quantified via ImageJ densitometry of
both IP and total lysate western blots.

proteins were found associated with Pyk2 in this system,
however only 18 of these were found specifically in
pUS28-expressing samples (Figure 4A). In contrast to
results seen in RSMC, nearly all of the proteins associated with Pyk2 in U373 were induced by signaling
(Figure 4B), revealing low baseline activity of Pyk2 in
these cells. Many of the same proteins binding to Pyk2
in response to pUS28 signaling were detected in samples
from both cell types (Table 1 &2 , boldface text). However, there were a number of proteins that were unique
to pUS28 signaling in U373. Importantly, several heat
shock proteins of the Hsp70 family (BiP, mortalin and
Hsc70) known to be involved in glioma tumorigenesis
[61-64] were found to complex with Pyk2 in response to
pUS28 signaling. Additionally, several regulators of the
Wnt/beta-catenin/Tcf signaling pathway, also implicated
in glioma pathogenesis [65,66] are associated with
pUS28-activated Pyk2 complexes (Table 2).

Discussion
In this paper, we examined the ability of the HCMVencoded chemokine receptor pUS28 to activate Pyk2
and determined the role of Pyk2 in pUS28 mediated
SMC migration (Figure 7). Pyk2 expression is limited to
a subset of cell types in vivo including brain, hematopoetic cells, endothelial cells, SMC and fibroblasts.
Interestingly, many of these cell types are capable of
undergoing migration events in response to various
external stimuli including integrin, growth factor,
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Table 2 Pyk2 binding partners in pUS28-expressing U373
CATEGORY

PROTEIN(S) IDENTIFIED
b-actin, a1-actin, a2-actin, Nectin-3 [100], Myosin-9, Myosin light chain-6, Tropomyosin-a1 [72,90,91]

Cytoskeleton Structure and
Dynamics
Signal Transduction

USP6 oncogene* [101], NIM1 kinase* [102], Copine-5* [103], Abl-interactor-2* [104], TFG [54]

Inflammation and Immunity

Immunoglobulin lambda light chain [97], NFB p105

Cellular Proliferation

TCF-4 [50,65], AF-17 [98], RTEL-1* [99,105,106], N-acetyltransferase-10 [107], Integrator complex subunit 6
[108]

Stress Response

BiP [61,109], Mortalin [62,110], Hsc70 [63,64]

Boldface font indicates proteins identified as Pyk2 associated in multiple cell types.
* indicates proteins identified with low abundance (<3 spectral hits on a single peptide).

hormone and chemokine-mediated signals. There is very
little consensus in the literature regarding the participation of Pyk2 in such migration events. Indeed, requirements for Pyk2 signaling, and downstream effectors of
Pyk2 activation are highly cell type and signal type-specific [28].
Pyk2 and migration in vascular smooth muscle

Migration of vascular SMC is induced by a variety of stimuli including growth factors, cytokines, extracellular
matrix (ECM) components and peptide hormones. Promigratory signaling in SMC is best understood in the
context of platelet-derived growth factor (PDGF) binding through receptor tyrosine kinases PDGFR-a and b.
PDGF-mediated migration in SMC is characterized by
Src-dependent activation of FAK, RhoA mediated activation of ROCK and subsequent phosphorylation and inhibition of myosin light chain phosphatase as well as
activation of various other effector molecules via ERK,
p38MAPK and JNK MAPK families [67]. Angiotensin II
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Figure 7 pUS28-mediated Pro-migratory Signaling in SMC.
Schematic model for known components of US28-mediated promigratory signaling in response to CC-chemokine ligands.

(Ang II) is another well-studied pro-migratory signal in
SMC. Ang II binding to the GPCR angiotensin receptor
type 1 (AT-1) initiates the only pro-migratory signaling
cascade in SMC previously reported to involve Pyk2
[68]. In this signaling context, Pyk2 is activated by PKCδ
[69] and signals to Rho/ROCK via association with
PDZ-RhoGEF [26]. Additionally, Pyk2 has been identified as an essential signaling scaffold linking GPCR signaling to MAP kinase activation via Src activation upon
binding to Tyr-402 autophosphorylated Pyk2 [31]. Activation of JNK and ERK MAP kinase pathways are necessary for Ang II-mediated SMC migration [26].
The results presented herein represent the first example of a chemokine-mediated pro-migratory signaling
cascade in VSMC involving Pyk2. We have previously
demonstrated that chemokine binding to the viral chemokine receptor pUS28 causes SMC migration via a
Src-mediated activation of FAK and ERK [17], and the
Ga12-mediated activation of RhoA and ROCK [16].
These results refine our understanding of the pUS28
receptor-proximal events leading to the activation of
RhoA via the ligand-dependent phosphorylation of Pyk2
at Tyr-402. Pyk2 kinase activity is dispensable for
pUS28-mediated migration in SMC, suggesting that
Pyk2 participates primarily as a signaling scaffold in
pUS28 pro-migratory signaling. We have previously
demonstrated that pUS28-induced SMC migration is
sensitive to the Src inhibitor PP-2 and that FAK functionally interacts with Src in pUS28-expressing cells stimulated with CCL5. We further demonstrated that Src
activation is upstream of FAK in this pathway [17].
Similarly, pUS28 can signal to Pyk2 in FAK-/- fibroblasts suggesting that Pyk2 activation is upstream or
independent of FAK in this signaling cascade. Our proteomics analysis of Pyk2 binding partners in the context
of pUS28 signaling revealed several novel proteins that
shed new insight into the function of Pyk2 in promigratory signaling. In particular, we show that Pyk2
interacts with several tropomyosin (TM) isoforms and
the TM interacting protein tropomodulin isoform 3
(Tmod3) in response to pUS28 signaling. These proteins
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are well-characterized regulators of actin polymerization
and cytoskeletal dynamics [70]. Tmod3 is broadly
expressed in cells with dynamic actin filament structures
and is unique among tropomodulin proteins in that, in
addition to regulating the capping of actin filament
pointed ends, it binds free actin monomers and may
regulate the nucleation of new actin filaments [71]. Our
discovery of an association of Pyk2 with TM isoforms is
novel and particularly intriguing. TM proteins regulate
the structure and specific properties of actin filaments
but the mechanisms of TM regulation remain obscure
[72]. One possible mechanism of TM regulation is phosphorylation. Indeed, the phosphorlyation of TM1 in
response to ERK signaling in endothelial cells increases
the formation of both actin stress fibers and focal adhesions contributing to increased cellular contractility [73].
Our results suggest that the Pyk2 signaling complex participates in cytoskeleton remodeling via modification of
Tmod and TM proteins. Taken together, these results
suggest that Pyk2 acts together with Src, FAK and other
adaptor molecules to promote pro-migratory signaling
and that Pyk2 phosphorylation at Tyr-402, is required
for the downstream activation of RhoA. Our finding
that the scaffolding activity of Pyk2 is separable from its
kinase activity is novel in the literature. In the context
of AngII-mediated SMC migration as well as migration
of endothelial cells, Pyk2 kinase activity is an essential
component of pro-migratory signaling [26,74].
pUS28 signaling and CMV-associated malignancy

In this paper, we explore the contribution of pUS28 signaling to Pyk2 in migration processes associated with
HCMV-mediated vascular disease. However, HCMV has
been implicated in other disease processes in which the
induction of cellular migration may play a role. In particular, HCMV infection has been associated with several
human malignancies including prostate and colon cancers as well as glioblastoma multiforme (GBM) [75].
GBM is the most common and most malignant type of
brain cancer and currently has no effective treatment
[76]. HCMV DNA is present in over 90% of human
malignant gliomas [1,77], suggesting a role for HCMV
in glioma oncogenesis. A recent report has strengthened
the connection between HCMV and GBM by demonstrating that vaccination against the HCMV tegument
protein pp65 can improve survival in GBM patients
[78]. However, the molecular mechanisms of HCMV
participation in glioma development remain unclear.
pUS28 signaling has recently been reported to produce a transformed phenotype in transfected NIH-3T3
cells characterized by increased proliferative capacity,
and increased expression of the pro-angiogenic marker
VEGF. In addition, the study demonstrated that WT
HCMV infection of a human glioblastoma cell line
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(U373) induces VEGF expression while a pUS28 deletion mutant of HCMV fails to induce VEGF upregulation in glioblastoma cells [10] implicating pUS28
signaling in glioma pathogenesis. However, this study
did not explore the contribution of pUS28 ligand binding to the observed phenotypes.
Pyk2 and glioma tumorigenesis

In addition to its role in vascular remodelling, Pyk2 has
been identified as a pro-metastatic and pro-angiogenic
molecule in several cancer models including small cell
lung cancer [79,80], prostate cancer [81-83] and glioblastoma [41,58-60]. A number of elegant studies by
Lipinski et. al. have established roles for Pyk2 and FAK
in glioma tumorigenesis both in vitro and in vivo. In
these studies, Pyk2 is demonstrated to promote migration and invasion of glioma cells while FAK controls
their proliferation. The authors demonstrate that the
migratory capacity of individual glioma cell lines can be
correlated to the relative levels of Pyk2 expression and
activation. Perhaps the most compelling evidence for the
role of Pyk2 and FAK in glioma tumor progression utilized an in vivo xenograft model of glioblastoma in
mice. In this study, Pyk2 deficient cells were observed to
invade only locally and survival was significantly
increased when mice were engrafted with Pyk2 or FAK
deficient glioma cells compared to mice engrafted with
wild-type glioma cells [60]. Our current study and previous work characterizing the pUS28-mediated activation of FAK suggest a mechanism for acceleration of
glioma tumor formation by HCMV via pUS28-mediated
signaling through the critical mediators of glioma tumor
progression, Pyk2 and FAK. Our results are consistent
with existing literature in which the Pyk2 FERM domain
is established as a target for reducing glioma cell migration [58,84]. Pyk2 undergoes dimerization and autophosphorylation upon FERM domain interaction with Ca2
+/calmodulin [30]. Therefore inhibition of the Pyk2
FERM domain by mutation or antibody targeting may
prevent dimerization and phosphorylation of Pyk2 at
Tyr-402 thereby preventing the activation of RhoA.
We observed the formation of a cell type specific Pyk2
complex in response to pUS28 signaling in U373 glioblastoma cells. This complex included several proteins
previously implicated in glioma tumorigenesis, but never
before identified as Pyk2 binding partners. Our data
suggests at least two novel mechanisms for the participation of Pyk2 and pUS28 in glioma tumorigenesis.
First, we identified TCF-4 and AF-17 binding to Pyk2 in
response to pUS28 signaling. Both proteins are members
of the Wnt/b-catenin signaling pathway that has
recently been linked to glioma progression [65,66].
Indeed, siRNA mediated inhibition of this pathway
decreases glioma proliferation and invasion capacity
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[65]. Interestingly, Pyk2 has been shown to phosphorylate b-catenin in endothelial cells [85] suggesting that
Pyk2 may be involved in the activation of canonical
b-catenin signaling in multiple cell types. Second, we discovered that pUS28 signaling caused Pyk2 to associate with
three members of the Hsp70 family of molecular chaperone
proteins. Interestingly, all three of these proteins are known
to be specifically upregulated in glioma tissue and play various roles in the progression of glioma tumorigenesis
[61-63] as well as other cancer models [86]. Mortalin, in
particular, is functionally regulated via tyrosine phosphorylation [87]. Our results suggest that Pyk2, or kinases associated with Pyk2 may play a role in regulating the function
of multiple Hsp70-family chaperones, thereby contributing
to the proliferation and survival of tumor cells.
These findings refine our understanding of the promigratory signaling pathways activated by pUS28 in
SMC and establish Pyk2 as an attractive target for the
treatment of CMV-mediated vascular disease because it
acts early in the pUS28 pro-migratory signaling cascade
and its expression is restricted to a few cell types, reducing the opportunities for off-target effects. Further,
these results suggest a role for HCMV pUS28 in pathologies associated with aberrant activation of Pyk2 including some malignancies.

Conclusions
In this report, we determined the involvement of Pyk2
in pUS28 signaling and cellular migration (Figure 7).
We found that Pyk2 autophosphorylation activity, but
not kinase activity, is necessary for HCMV-mediated
SMC migration. Furthermore, pUS28 signaling causes
ligand-dependent phosphorylation of Pyk2 at Tyr-402
independent of pUS28 signaling to FAK. Pyk2 is incorporated into an active kinase complex in CCL5 stimulated SMC expressing pUS28. Pyk2 associates with a
number of other proteins in response to pUS28 signaling including kinases, signaling molecules, cytoskeletal
proteins, and molecular chaperones. We determined
that although the Pyk2 autophosphorylation mutant
(F402Y) does not prevent the formation of an activated
kinase complex, it exerts a dominant negative effect on
SMC migration by preventing the pUS28-mediated activation of the small G-protein RhoA. Importantly, the
effect of pUS28 activating Pyk2 is not cell-type specific
as we observed comparable activation of Pyk2 and RhoA
via pUS28 signaling in U373 glioblastoma cells. This
finding suggests that pUS28 signaling to Pyk2 may be
important in glioma cell motility. In addition to establishing Pyk2 as a potential target in the treatment of
HCMV-mediated vascular disease, and establishing a
number of novel Pyk2-associated proteins, these results
provide a potential link between pUS28 and CMV-associated malignancy.
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Additional material
Additional file 1: Table S1: Mass Spectrometry Data for Pyk2
Complexes in RSMC. For each Pyk2 associated protein, spectral hits are
shown for each unique peptide over the timecourse of stimulation. Total
spectral hits per peptide are shown to the right of the timecourse for
each condition. Total peptides and spectral hits for each timepoint are
shown below the list of peptides for each protein.
Additional file 2: Table S2: Mass Spectrometry Data for Pyk2
Complexes in U373. For each Pyk2 associated protein, spectral hits are
shown for each unique peptide over the timecourse of stimulation. Total
spectral hits per peptide are shown to the right of the timecourse for
each condition. Total peptides and spectral hits for each timepoint are
shown below the list of peptides for each protein.
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